Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Yu Y, Shi X, Wang X, Zhang P, Bai O, Li Y. Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases. Cell Biosci 2022;12:30. [PMID: 35279210 PMCID: PMC8917635 DOI: 10.1186/s13578-022-00763-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Accepted: 02/14/2022] [Indexed: 12/02/2022] Open

For:	Yu Y, Shi X, Wang X, Zhang P, Bai O, Li Y. Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases. Cell Biosci 2022;12:30. [PMID: 35279210 PMCID: PMC8917635 DOI: 10.1186/s13578-022-00763-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Accepted: 02/14/2022] [Indexed: 12/02/2022] Open

Number

Cited by Other Article(s)

Pitchai FNN, Tanner EJ, Khetan N, Vasen G, Levrel C, Kumar AJ, Pandey S, Ordonez T, Barnette P, Spencer D, Jung SY, Glazier J, Thompson C, Harvey-Vera A, Son HI, Son HI, Strathdee SA, Holguin L, Urak R, Burnett J, Burgess W, Busman-Sahay K, Estes JD, Hessell A, Fennessey CM, Keele BF, Haigwood NL, Weinberger LS. Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates. Science 2024;385:eadn5866. [PMID: 39116226 DOI: 10.1126/science.adn5866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Accepted: 06/06/2024] [Indexed: 08/10/2024]

Affiliation(s)

Fathima N Nagoor Pitchai Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA Gladstone Institute of Virology, University of California, San Francisco, CA, USA
Elizabeth J Tanner Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA Gladstone Institute of Virology, University of California, San Francisco, CA, USA
Neha Khetan Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA Gladstone Institute of Virology, University of California, San Francisco, CA, USA
Gustavo Vasen Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA Gladstone Institute of Virology, University of California, San Francisco, CA, USA
Clara Levrel Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA Gladstone Institute of Virology, University of California, San Francisco, CA, USA
Arjun J Kumar Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA Gladstone Institute of Virology, University of California, San Francisco, CA, USA Department of Bioengineering, University of Washington, Seattle, WA, USA
Shilpi Pandey Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA
Tracy Ordonez Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA
Philip Barnette Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA
David Spencer Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA Absci Corporation, Vancouver, WA, USA
Seung-Yong Jung Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA
Joshua Glazier Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA
Cassandra Thompson Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA
Alicia Harvey-Vera
Hye-In Son Global Health Sciences, Department of Medicine, University of California San Diego, La Jolla, CA, USA US-Mexico Border Health Commission, Tijuana, Mexico Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA
Hye-In Son Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA
Steffanie A Strathdee Global Health Sciences, Department of Medicine, University of California San Diego, La Jolla, CA, USA
Leo Holguin Global Health Sciences, Department of Medicine, University of California San Diego, La Jolla, CA, USA
Ryan Urak Center for Gene Therapy, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA
John Burnett Center for Gene Therapy, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, USA
William Burgess Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA
Kathleen Busman-Sahay Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA
Jacob D Estes Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA Faculty of Health, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark School of Health and Biomedical Sciences College of Science, Engineering and Health RMIT University, Melbourne, Australia
Ann Hessell Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA
Christine M Fennessey AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
Brandon F Keele AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
Nancy L Haigwood Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA
Leor S Weinberger Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA Gladstone Institute of Virology, University of California, San Francisco, CA, USA Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA

Collapse

Abalo KD, Smedby KE, Ekberg S, Eloranta S, Pahnke S, Albertsson-Lindblad A, Jerkeman M, Glimelius I. Secondary malignancies among mantle cell lymphoma patients. Eur J Cancer 2023;195:113403. [PMID: 37952281 DOI: 10.1016/j.ejca.2023.113403] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 10/03/2023] [Accepted: 10/20/2023] [Indexed: 11/14/2023]

Abstract

PURPOSE

With modern treatments, mantle cell lymphoma (MCL) patients more frequently experience long-lasting remission resulting in a growing population of long-term survivors. Follow-up care includes identification and management of treatment-related late-effects, such as secondary malignancies (SM). We conducted a population-based study to describe the burden of SM in MCL patients.

METHODS

All patients with a primary diagnosis of MCL, aged ≥ 18 years and diagnosed between 2000 and 2017 in Sweden were included along with up to 10 individually matched population comparators. Follow-up was from twelve months after diagnosis/matching until death, emigration, or December 2019, whichever occurred first. Rates of SM among patients and comparators were estimated using the Anderson-Gill method (accounting for repeated events) and presented as hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age at diagnosis, calendar year, sex, and the number of previous events.

RESULTS

Overall, 1 452 patients and 13 992 comparators were followed for 6.6 years on average. Among patients, 230 (16%) developed at least one SM, and 264 SM were observed. Relative to comparators, patients had a higher rate of SM, HRadj= 1.6 (95%CI:1.4-1.8), and higher rates were observed across all primary treatment groups: the Nordic-MCL2 protocol, R-CHOP, R-bendamustine, ibrutinib, lenalidomide, and R-CHOP/Cytarabine. Compared to Nordic-MCL2, treatment with R-bendamustine was independently associated with an increased risk of SM, HRadj= 2.0 (95%CI:1.3-3.2). Risk groups among patients were those with a higher age at diagnosis (p < 0.001), males (p = 0.006), and having a family history of lymphoma (p = 0.009). Patients had preferably higher risk of melanoma, other neoplasms of the skin and other hematopoietic and lymphoid malignancies.

CONCLUSIONS

MCL survivors have an increased risk of SM, particularly if treated with R-bendamustine. The intensive treatments needed for long-term remissions are a concern, and transition to treatment protocols with sustained efficacy but with a lower risk of SM is needed.

Collapse

Wang SS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol 2023;60:255-266. [PMID: 38242772 PMCID: PMC10962251 DOI: 10.1053/j.seminhematol.2023.11.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 11/15/2023] [Accepted: 11/21/2023] [Indexed: 01/21/2024]

Abstract

As the most common non-Hodgkin lymphoma subtype, diffuse large B-cell lymphoma (DLBCL) incidence patterns generally parallel that for NHL overall. Globally, DLBCL accounts for a third of all NHLs, ranging between 20% and 50% by country. Based on United States (U.S.) cancer registry data, age-standardized incidence rate for DLBCL was 7.2 per 100,000. DLBCL incidence rises with age and is generally higher in males than females; in the U.S., incidence is highest among non-Hispanic whites (9.2/100,000). Like NHL incidence, DLBCL incidence rose in the first half of the 20th century but has largely plateaued. However, there is some evidence that incidence rates are rising in areas of historically low rates, such as Asia; there are also estimates for rising DLBCL incidence in the near future due to the changing demographics in developed countries whose aging population is growing. Established risk factors for DLBCL include those that result in severe immune deficiency such as HIV/AIDS, inherited immunodeficiency syndromes, and organ transplant recipients. Factors that lead to chronic immune dysregulations are also established risk factors, and include a number of autoimmune conditions (eg, Sjögren syndrome, systemic lupus erythematosus, rheumatoid arthritis), viral infections (eg, HIV, KSHV/HHV8, HCV, EBV), and obesity. Family history of NHL/DLBCL, personal history of cancer, and multiple genetic susceptibility loci are also well-established risk factors for DLBCL. There is strong evidence for multiple environmental exposures in DLBCL etiology, including exposure to trichloroethylene, benzene, and pesticides and herbicides, with recent associations noted with glyphosate. There is also strong evidence for associations with other viruses, such as HBV. Recent estimates suggest that obesity accounts for nearly a quarter of DLBCLs that develop, but despite recent gains in the understanding of DLBCL etiology, the majority of disease remain unexplained. An understanding of the host and environmental contributions to disease etiology, and concerted efforts to expand our understanding to multiple race/ethnic groups, will be essential for constructing clinically relevant risk prediction models and develop effective strategies for disease prevention.

Collapse